Scaling Artificial Intelligence for Prostate Cancer Detection on MRI towards Organized Screening and Primary Diagnosis in a Global, Multiethnic Population (Study Protocol)

Fuente: arXiv
Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Saha, Anindo, Bosma, Joeran S., Twilt, Jasper J., Ng, Alexander B. C. D., Asif, Aqua, Magudia, Kirti, Larson, Peder, Xie, Qinglin, Zhang, Xiaodong, Minh, Chi Pham, Gitau, Samuel N., Schoots, Ivo G., Boomsma, Martijn F., Cuocolo, Renato, Papanikolaou, Nikolaos, Regge, Daniele, Yakar, Derya, Elschot, Mattijs, Veltman, Jeroen, Turkbey, Baris, Obuchowski, Nancy A., Fütterer, Jurgen J., Padhani, Anwar R., Ahmed, Hashim U., Nordström, Tobias, Eklund, Martin, Kasivisvanathan, Veeru, de Rooij, Maarten, Huisman, Henkjan
Format: Preprint
Veröffentlicht: 2025
Schlagworte:
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1866911149756252160
author Saha, Anindo
Bosma, Joeran S.
Twilt, Jasper J.
Ng, Alexander B. C. D.
Asif, Aqua
Magudia, Kirti
Larson, Peder
Xie, Qinglin
Zhang, Xiaodong
Minh, Chi Pham
Gitau, Samuel N.
Schoots, Ivo G.
Boomsma, Martijn F.
Cuocolo, Renato
Papanikolaou, Nikolaos
Regge, Daniele
Yakar, Derya
Elschot, Mattijs
Veltman, Jeroen
Turkbey, Baris
Obuchowski, Nancy A.
Fütterer, Jurgen J.
Padhani, Anwar R.
Ahmed, Hashim U.
Nordström, Tobias
Eklund, Martin
Kasivisvanathan, Veeru
de Rooij, Maarten
Huisman, Henkjan
author_facet Saha, Anindo
Bosma, Joeran S.
Twilt, Jasper J.
Ng, Alexander B. C. D.
Asif, Aqua
Magudia, Kirti
Larson, Peder
Xie, Qinglin
Zhang, Xiaodong
Minh, Chi Pham
Gitau, Samuel N.
Schoots, Ivo G.
Boomsma, Martijn F.
Cuocolo, Renato
Papanikolaou, Nikolaos
Regge, Daniele
Yakar, Derya
Elschot, Mattijs
Veltman, Jeroen
Turkbey, Baris
Obuchowski, Nancy A.
Fütterer, Jurgen J.
Padhani, Anwar R.
Ahmed, Hashim U.
Nordström, Tobias
Eklund, Martin
Kasivisvanathan, Veeru
de Rooij, Maarten
Huisman, Henkjan
contents In this intercontinental, confirmatory study, we include a retrospective cohort of 22,481 MRI examinations (21,288 patients; 46 cities in 22 countries) to train and externally validate the PI-CAI-2B model, i.e., an efficient, next-generation iteration of the state-of-the-art AI system that was developed for detecting Gleason grade group $\geq$2 prostate cancer on MRI during the PI-CAI study. Of these examinations, 20,471 cases (19,278 patients; 26 cities in 14 countries) from two EU Horizon projects (ProCAncer-I, COMFORT) and 12 independent centers based in Europe, North America, Asia and Africa, are used for training and internal testing. Additionally, 2010 cases (2010 patients; 20 external cities in 12 countries) from population-based screening (STHLM3-MRI, IP1-PROSTAGRAM trials) and primary diagnostic settings (PRIME trial) based in Europe, North and South Americas, Asia and Australia, are used for external testing. Primary endpoint is the proportion of AI-based assessments in agreement with the standard of care diagnoses (i.e., clinical assessments made by expert uropathologists on histopathology, if available, or at least two expert urogenital radiologists in consensus; with access to patient history and peer consultation) in the detection of Gleason grade group $\geq$2 prostate cancer within the external testing cohorts. Our statistical analysis plan is prespecified with a hypothesis of diagnostic interchangeability to the standard of care at the PI-RADS $\geq$3 (primary diagnosis) or $\geq$4 (screening) cut-off, considering an absolute margin of 0.05 and reader estimates derived from the PI-CAI observer study (62 radiologists reading 400 cases). Secondary measures comprise the area under the receiver operating characteristic curve (AUROC) of the AI system stratified by imaging quality, patient age and patient ethnicity to identify underlying biases (if any).
format Preprint
id arxiv_https___arxiv_org_abs_2508_03762
institution arXiv
publishDate 2025
record_format arxiv
spellingShingle Scaling Artificial Intelligence for Prostate Cancer Detection on MRI towards Organized Screening and Primary Diagnosis in a Global, Multiethnic Population (Study Protocol)
Saha, Anindo
Bosma, Joeran S.
Twilt, Jasper J.
Ng, Alexander B. C. D.
Asif, Aqua
Magudia, Kirti
Larson, Peder
Xie, Qinglin
Zhang, Xiaodong
Minh, Chi Pham
Gitau, Samuel N.
Schoots, Ivo G.
Boomsma, Martijn F.
Cuocolo, Renato
Papanikolaou, Nikolaos
Regge, Daniele
Yakar, Derya
Elschot, Mattijs
Veltman, Jeroen
Turkbey, Baris
Obuchowski, Nancy A.
Fütterer, Jurgen J.
Padhani, Anwar R.
Ahmed, Hashim U.
Nordström, Tobias
Eklund, Martin
Kasivisvanathan, Veeru
de Rooij, Maarten
Huisman, Henkjan
Image and Video Processing
Computer Vision and Pattern Recognition
In this intercontinental, confirmatory study, we include a retrospective cohort of 22,481 MRI examinations (21,288 patients; 46 cities in 22 countries) to train and externally validate the PI-CAI-2B model, i.e., an efficient, next-generation iteration of the state-of-the-art AI system that was developed for detecting Gleason grade group $\geq$2 prostate cancer on MRI during the PI-CAI study. Of these examinations, 20,471 cases (19,278 patients; 26 cities in 14 countries) from two EU Horizon projects (ProCAncer-I, COMFORT) and 12 independent centers based in Europe, North America, Asia and Africa, are used for training and internal testing. Additionally, 2010 cases (2010 patients; 20 external cities in 12 countries) from population-based screening (STHLM3-MRI, IP1-PROSTAGRAM trials) and primary diagnostic settings (PRIME trial) based in Europe, North and South Americas, Asia and Australia, are used for external testing. Primary endpoint is the proportion of AI-based assessments in agreement with the standard of care diagnoses (i.e., clinical assessments made by expert uropathologists on histopathology, if available, or at least two expert urogenital radiologists in consensus; with access to patient history and peer consultation) in the detection of Gleason grade group $\geq$2 prostate cancer within the external testing cohorts. Our statistical analysis plan is prespecified with a hypothesis of diagnostic interchangeability to the standard of care at the PI-RADS $\geq$3 (primary diagnosis) or $\geq$4 (screening) cut-off, considering an absolute margin of 0.05 and reader estimates derived from the PI-CAI observer study (62 radiologists reading 400 cases). Secondary measures comprise the area under the receiver operating characteristic curve (AUROC) of the AI system stratified by imaging quality, patient age and patient ethnicity to identify underlying biases (if any).
title Scaling Artificial Intelligence for Prostate Cancer Detection on MRI towards Organized Screening and Primary Diagnosis in a Global, Multiethnic Population (Study Protocol)
topic Image and Video Processing
Computer Vision and Pattern Recognition
url https://arxiv.org/abs/2508.03762